Precisis AG has increased its stock to approximately 1.5 million Euros by issuing 350,000 new common registered shares. The approved capital has been partially utilised for this step. The new shares pay dividends as of 1 January 2017. They pass to two entrepreneurial families within the framework of a bookbuilding process by shareholder resolution in November 2016. The increase in stock gives Precisis AG a gross revenue of approximately 3.5 million Euros. In the light of the successful technological development of the neurostimulator device EASEE©, the capital increase should secure the clinical phase.
Chairwoman Angela Liedler explains the mission of Precisis AG: “Our roots are in neurosurgery, and customised medical technology is what drives us. As an innovative company we strive to implement the therapy of functional brain disease with micro-invasive, intelligent systems.”
Funds from a capital increase are used for clinical studies of EASEE®
Since 2014 Precisis AG has been developing an easy-to-use device for the targeted therapy of brain disease originating from the cortical areas of the brain. This includes, for instance, many forms of focal epilepsy. Now that the technological development is by and large completed, an initial study with implants in patients is to be carried out.
The first clinical data on patients and the preparation of the authorisation of EASEE© as a medical device are to be secured from the funds raised by the capital increase.